EPS accretion is not value creation in a contested acquisition
Bolt Ltd, an auto-components maker, is negotiating to acquire Nut Ltd. Bolt has 60 crore shares, FY2025 profit after tax of ₹240 crore, and trades at ₹80 - a P/E of 20. Nut has 30 crore shares, profit after tax of ₹120 crore, and trades at ₹60. Bolt's bankers value Nut's enterprise value at ₹2,286 crore, using a WACC of 11% and 4% growth; Nut carries ₹200 crore of net debt. A peer set trades at a median P/E of 16. The advisers estimate recurring pre-tax synergies of ₹80 crore a year from procurement and distribution, fully realised from year 2, with one-off pre-tax integration costs of ₹150 crore in year 1. The tax rate is 25%. Bolt's board wants the deal to be EPS-accretive in year 1 and to create value for Bolt's shareholders. A rival industrial group has now indicated it will bid ₹88 per Nut share.
1. Value Nut and determine the maximum price Bolt can pay without destroying value for its own shareholders. Express it per share and as a premium to the market price.
Read the worked answer
Standalone value
- DCF: enterprise value ₹2,286 crore less net debt ₹200 crore = equity value ₹2,086 crore → ₹69.5 per share (30 crore shares).
- Multiples cross-check: peer P/E 16 × PAT ₹120 crore = ₹1,920 crore → ₹64 per share.
The two methods bracket the answer. The DCF sits above the market price of ₹60, so the market is already discounting something - either scepticism about the growth assumption or general small-cap illiquidity. I would use the DCF as the central intrinsic value with the multiple as a floor, and record that the ₹5.5 per share gap between them is the valuation risk in the deal.
Synergy value
| ₹ crore |
|---|
| Pre-tax synergies |
| Post-tax (× 0.75) |
| Perpetuity value at end of year 1 (60 / 0.11, no growth assumed) |
| Discounted one year (fully realised from year 2) |
| Integration costs, post-tax (150 × 0.75), year 1 |
| Net synergy value |
Note that integration costs are deducted in full while synergies are assumed to arrive in perpetuity and to be delivered flawlessly. That is the most favourable defensible assumption; the case has no cushion beyond it.
Maximum price
2,086 + 378.5 = ₹2,464.5 crore, or ₹82.15 per share - a 37% premium to the ₹60 market price and an 18% premium to the DCF value.
Above ₹82.15, every rupee paid comes out of Bolt's shareholders' pockets and goes to Nut's. The board's walk-away price is a value number, not a negotiating posture: it should be tabled in the first board meeting, before any price is named, and minuted.
2. At ₹72 per share paid in Bolt shares, compute the exchange ratio, the year-1 and year-2 EPS effect and the EPS-neutral ratio. Explain why the EPS result and the value result can point in different directions.
Read the worked answer
Exchange ratio and share count
Offer of ₹72 against Bolt's ₹80: ratio = 72 / 80 = 0.9 Bolt shares per Nut share. New shares = 30 × 0.9 = 27 crore; post-deal shares = 87 crore.
EPS
| ₹ crore | EPS (₹) | vs ₹4.00 | |
|---|---|---|---|
| Bolt standalone | 240 | 4.00 | - |
| Combined, no synergies, before integration costs | 360 | 4.138 | +3.4% |
| Year 1, integration costs expensed (post-tax 112.5) | 247.5 | 2.845 | −28.9% |
| Year 2, full synergies (360 + 60) | 420 | 4.828 | +20.7% |
Year 1 is dilutive on a reported basis and accretive on an underlying basis. Which one the board is shown is a governance question, not an arithmetic one: the integration cost is a real cash outflow and cannot be excluded from value, only from the run-rate presentation, and if it is excluded the exclusion must be quantified and repeated for every deal.
EPS-neutral ratios
- Excluding synergies: 360 / 4.00 = 90 crore shares → 30 crore new → ratio 1.0 → ₹80 per Nut share.
- Including full synergies: 420 / 4.00 = 105 crore shares → 45 crore new → ratio 1.5 → ₹120 per Nut share.
The gap between ₹80 and ₹120 is entirely the value of synergies that Bolt has not yet delivered.
Why EPS and value diverge. Bolt's P/E of 20 buys Nut's earnings yield at 72 (5.6%) against Bolt's own 5.0%, so the arithmetic is accretive even at a premium. But EPS accretion measures the price paid relative to Bolt's own rating, not relative to what Nut is worth. Bolt's walk-away value is ₹82.15, so at ₹72 the deal creates roughly ₹300 crore of value for Bolt shareholders; at ₹88 it destroys ₹175 crore, even though year-2 EPS rises 12.9%. Any board paper that leads with accretion and buries the value analysis has the argument backwards.
3. The rival has bid ₹88. The MD wants to go to ₹95 to win. Advise the board, supporting your answer with numbers and with the structural alternatives available.
Read the worked answer
What ₹88 and ₹95 actually cost
| ₹88 | ₹95 | |
|---|---|---|
| Consideration (₹ crore) | 2,640 | 2,850 |
| Exchange ratio | 1.10 | 1.1875 |
| New shares (crore) | 33.00 | 35.625 |
| Post-deal shares (crore) | 93.00 | 95.625 |
| EPS, no synergies | 3.871 (−3.2%) | 3.764 (−5.9%) |
| EPS, full synergies | 4.516 (+12.9%) | 4.392 (+9.8%) |
| Value paid over the ₹2,464.5 crore walk-away | 175.5 | 385.5 |
The argument
- Both prices are above Bolt's walk-away value of ₹2,464.5 crore. At ₹88 Bolt transfers ₹175 crore of its shareholders' value to Nut's; at ₹95, ₹385 crore. Winning at ₹95 is losing by a larger amount, more visibly.
- The EPS figures are a trap. Year-2 accretion survives at ₹95 only because ₹60 crore of synergy has been capitalised at 11% and credited to the deal. If half the synergy slips, or arrives two years late, the accretion disappears while the overpayment does not. Bolt would then have paid ₹95 for a business worth ₹69.5 plus synergies it did not deliver.
- The rival may value the assets differently - a strategic buyer with an existing distribution network can extract more. Bolt cannot know that, and bidding against an unknown valuation is not a strategy. The correct inference from a bid above your walk-away is that the asset is worth more to someone else.
Recommendation. Do not raise. Announce a disciplined withdrawal at ₹82-83 and say publicly why: the price exceeded the value to Bolt shareholders. That has a cost - the market may read it as weakness - but it is far cheaper than a value-destructive deal, and it protects the board's credibility for the next one.
Alternatives worth tabling
- A capped structure: ₹74 cash or shares upfront plus an earn-out of up to ₹14 per share payable only if the ₹80 crore synergy run-rate is achieved by year 2. This transfers the synergy risk to the sellers and keeps the headline value inside the walk-away.
- Buy the distribution assets or a 26% strategic stake instead of the whole company, capturing part of the synergy at a fraction of the control premium.
- Walk away and return after the rival has integrated; overpaying buyers frequently under-deliver and re-sell.
Process. A s.232 scheme requires an independent valuation and a fairness opinion; the board minute should record the walk-away value, the synergy assumptions and the reasons for declining, so that the decision can be defended to shareholders and, if necessary, to the regulator.